FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2155319477> ?p ?o ?g. }

• W2155319477 endingPage "1377" @default.
• W2155319477 startingPage "1371" @default.
• W2155319477 abstract "Sunitinib has shown antitumor activity with a manageable safety profile as metastatic renal cell carcinoma (RCC) treatment, when given by the standard intermittent schedule as well as a continuous daily dosing (CDD) schedule. A trial was conducted to compare the schedules.Patients with treatment-naive, clear cell advanced RCC were randomly assigned 1:1 to receive sunitinib 50 mg/d for 4 weeks followed by 2 weeks off treatment (schedule 4/2; n = 146) or 37.5 mg/d on the CDD schedule (n = 146) for up to 2 years. The primary end point was time to tumor progression.Median time to tumor progression was 9.9 months for schedule 4/2 and 7.1 months for the CDD schedule (hazard ratio, 0.77; 95% CI, 0.57 to 1.04; P = .090). No significant difference was observed in overall survival (23.1 v 23.5 months; P = .615), commonly reported adverse events, or patient-reported kidney cancer symptoms. Schedule 4/2 was statistically superior to CDD in time to deterioration, a composite end point of death, progression, and disease-related symptoms (P = .034). CONCLUSION; There was no benefit in efficacy or safety for continuous dosing of sunitinib compared with the approved 50 mg/d dose on schedule 4/2. Given the numerically longer time to tumor progression with the approved 50 mg/d dose on schedule 4/2, adherence to this dose and schedule remains the treatment goal for patients with advanced RCC." @default.
• W2155319477 created "2016-06-24" @default.
• W2155319477 creator A5001214769 @default.
• W2155319477 creator A5010671566 @default.
• W2155319477 creator A5011152885 @default.
• W2155319477 creator A5028479135 @default.
• W2155319477 creator A5028489277 @default.
• W2155319477 creator A5039180386 @default.
• W2155319477 creator A5040594266 @default.
• W2155319477 creator A5050649350 @default.
• W2155319477 creator A5051429729 @default.
• W2155319477 creator A5059063118 @default.
• W2155319477 creator A5061697254 @default.
• W2155319477 creator A5061916244 @default.
• W2155319477 creator A5063376558 @default.
• W2155319477 creator A5064227174 @default.
• W2155319477 creator A5072075374 @default.
• W2155319477 creator A5072800302 @default.
• W2155319477 creator A5080507578 @default.
• W2155319477 date "2012-04-20" @default.
• W2155319477 modified "2023-10-17" @default.
• W2155319477 title "Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma" @default.
• W2155319477 cites W1965664963 @default.
• W2155319477 cites W2001015184 @default.
• W2155319477 cites W2024586523 @default.
• W2155319477 cites W2040143310 @default.
• W2155319477 cites W2092773777 @default.
• W2155319477 cites W2099088585 @default.
• W2155319477 cites W2099752220 @default.
• W2155319477 cites W2103506609 @default.
• W2155319477 cites W2105258029 @default.
• W2155319477 cites W2105677187 @default.
• W2155319477 cites W2139248078 @default.
• W2155319477 cites W2143782771 @default.
• W2155319477 cites W2149456801 @default.
• W2155319477 cites W2153331460 @default.
• W2155319477 cites W2589244573 @default.
• W2155319477 doi "https://doi.org/10.1200/jco.2011.36.4133" @default.
• W2155319477 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22430274" @default.
• W2155319477 hasPublicationYear "2012" @default.
• W2155319477 type Work @default.
• W2155319477 sameAs 2155319477 @default.
• W2155319477 citedByCount "250" @default.
• W2155319477 countsByYear W21553194772012 @default.
• W2155319477 countsByYear W21553194772013 @default.
• W2155319477 countsByYear W21553194772014 @default.
• W2155319477 countsByYear W21553194772015 @default.
• W2155319477 countsByYear W21553194772016 @default.
• W2155319477 countsByYear W21553194772017 @default.
• W2155319477 countsByYear W21553194772018 @default.
• W2155319477 countsByYear W21553194772019 @default.
• W2155319477 countsByYear W21553194772020 @default.
• W2155319477 countsByYear W21553194772021 @default.
• W2155319477 countsByYear W21553194772022 @default.
• W2155319477 countsByYear W21553194772023 @default.
• W2155319477 crossrefType "journal-article" @default.
• W2155319477 hasAuthorship W2155319477A5001214769 @default.
• W2155319477 hasAuthorship W2155319477A5010671566 @default.
• W2155319477 hasAuthorship W2155319477A5011152885 @default.
• W2155319477 hasAuthorship W2155319477A5028479135 @default.
• W2155319477 hasAuthorship W2155319477A5028489277 @default.
• W2155319477 hasAuthorship W2155319477A5039180386 @default.
• W2155319477 hasAuthorship W2155319477A5040594266 @default.
• W2155319477 hasAuthorship W2155319477A5050649350 @default.
• W2155319477 hasAuthorship W2155319477A5051429729 @default.
• W2155319477 hasAuthorship W2155319477A5059063118 @default.
• W2155319477 hasAuthorship W2155319477A5061697254 @default.
• W2155319477 hasAuthorship W2155319477A5061916244 @default.
• W2155319477 hasAuthorship W2155319477A5063376558 @default.
• W2155319477 hasAuthorship W2155319477A5064227174 @default.
• W2155319477 hasAuthorship W2155319477A5072075374 @default.
• W2155319477 hasAuthorship W2155319477A5072800302 @default.
• W2155319477 hasAuthorship W2155319477A5080507578 @default.
• W2155319477 hasConcept C126322002 @default.
• W2155319477 hasConcept C126894567 @default.
• W2155319477 hasConcept C143998085 @default.
• W2155319477 hasConcept C197934379 @default.
• W2155319477 hasConcept C203092338 @default.
• W2155319477 hasConcept C207103383 @default.
• W2155319477 hasConcept C2777288759 @default.
• W2155319477 hasConcept C2777472916 @default.
• W2155319477 hasConcept C2779490328 @default.
• W2155319477 hasConcept C44249647 @default.
• W2155319477 hasConcept C535046627 @default.
• W2155319477 hasConcept C71924100 @default.
• W2155319477 hasConceptScore W2155319477C126322002 @default.
• W2155319477 hasConceptScore W2155319477C126894567 @default.
• W2155319477 hasConceptScore W2155319477C143998085 @default.
• W2155319477 hasConceptScore W2155319477C197934379 @default.
• W2155319477 hasConceptScore W2155319477C203092338 @default.
• W2155319477 hasConceptScore W2155319477C207103383 @default.
• W2155319477 hasConceptScore W2155319477C2777288759 @default.
• W2155319477 hasConceptScore W2155319477C2777472916 @default.
• W2155319477 hasConceptScore W2155319477C2779490328 @default.
• W2155319477 hasConceptScore W2155319477C44249647 @default.
• W2155319477 hasConceptScore W2155319477C535046627 @default.
• W2155319477 hasConceptScore W2155319477C71924100 @default.
• W2155319477 hasIssue "12" @default.

• next